Chaten D Jessel1, Abdullah Al Maruf1,2,3,4, Anita Oomen5, Paul D Arnold1,2,5,6, Chad A Bousman1,2,3,5,6. 1. The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta. 2. Department of Psychiatry, University of Calgary, Calgary, Alberta. 3. Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta. 4. College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba. 5. Department of Medical Genetics, University of Calgary, Calgary, Alberta. 6. Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta.
Abstract
OBJECTIVE: To assess knowledge, attitudes, and barriers as well as ethical, legal and social concerns towards pharmacogenetic (PGx) testing among pediatric psychiatrists and pediatricians in Alberta, Canada. METHOD: An anonymous electronic survey was sent to pediatric psychiatrists (n = 49) and pediatricians (n = 93) in Alberta. RESULTS: A total of 20 surveys were completed (response rate = 14%). Respondents agreed that PGx testing is clinically useful and a majority believed testing had the potential to aid in medication selection, dosing, switching, augmentation, and deprescribing, particularly among children with treatment-resistant conditions. However, most respondents could not identify an appropriate lab to perform testing, did not have the necessary training to interpret PGx results, and did not have access to experts that could assist them in interpreting results. CONCLUSION: The findings suggest additional PGx education and training is required to boost self-efficacy and uptake of PGx testing among pediatric psychiatrists and pediatricians in Alberta, Canada. In addition, local and global efforts to develop clinical practice guidelines, provide clear legal guidance, and ensure equitable access to testing may facilitate the implementation of PGx-informed prescribing.
OBJECTIVE: To assess knowledge, attitudes, and barriers as well as ethical, legal and social concerns towards pharmacogenetic (PGx) testing among pediatric psychiatrists and pediatricians in Alberta, Canada. METHOD: An anonymous electronic survey was sent to pediatric psychiatrists (n = 49) and pediatricians (n = 93) in Alberta. RESULTS: A total of 20 surveys were completed (response rate = 14%). Respondents agreed that PGx testing is clinically useful and a majority believed testing had the potential to aid in medication selection, dosing, switching, augmentation, and deprescribing, particularly among children with treatment-resistant conditions. However, most respondents could not identify an appropriate lab to perform testing, did not have the necessary training to interpret PGx results, and did not have access to experts that could assist them in interpreting results. CONCLUSION: The findings suggest additional PGx education and training is required to boost self-efficacy and uptake of PGx testing among pediatric psychiatrists and pediatricians in Alberta, Canada. In addition, local and global efforts to develop clinical practice guidelines, provide clear legal guidance, and ensure equitable access to testing may facilitate the implementation of PGx-informed prescribing.
Authors: Henry M Dunnenberger; Matthew Biszewski; Gillian C Bell; Annette Sereika; Holley May; Samuel G Johnson; Peter J Hulick; Janardan Khandekar Journal: Am J Health Syst Pharm Date: 2016-12-01 Impact factor: 2.637
Authors: J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar Journal: Clin Pharmacol Ther Date: 2011-03-16 Impact factor: 6.875
Authors: J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl Journal: Clin Pharmacol Ther Date: 2017-02-13 Impact factor: 6.875
Authors: Amina M Bagher; Thikryat Neamatallah; Ghadeer Balto; Lina Almikhy; Sara S Almutairi; Mohammed O Abushal; Khlood Baghlaf; Sara M Bagher Journal: Saudi Pharm J Date: 2020-12-30 Impact factor: 4.330